- Home
- COCH vs CING Comparison
COCH vs CING Comparison
Compare COCH & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- CING
- Stock Information
- Founded
- COCH 1995
- CING 2012
- Country
- COCH United States
- CING United States
- Employees
- COCH N/A
- CING N/A
- Industry
- COCH Blank Checks
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- CING Health Care
- Exchange
- COCH Nasdaq
- CING Nasdaq
- Market Cap
- COCH 25.2M
- CING 22.0M
- IPO Year
- COCH N/A
- CING 2021
- Fundamental
- Price
- COCH $1.47
- CING $4.09
- Analyst Decision
- COCH Strong Buy
- CING Strong Buy
- Analyst Count
- COCH 2
- CING 4
- Target Price
- COCH $9.25
- CING $31.00
- AVG Volume (30 Days)
- COCH 7.4M
- CING 156.0K
- Earning Date
- COCH 11-13-2025
- CING 11-06-2025
- Dividend Yield
- COCH N/A
- CING N/A
- EPS Growth
- COCH N/A
- CING N/A
- EPS
- COCH N/A
- CING N/A
- Revenue
- COCH $222,000.00
- CING N/A
- Revenue This Year
- COCH $4.27
- CING N/A
- Revenue Next Year
- COCH $23.37
- CING N/A
- P/E Ratio
- COCH N/A
- CING N/A
- Revenue Growth
- COCH N/A
- CING N/A
- 52 Week Low
- COCH $0.74
- CING $3.02
- 52 Week High
- COCH $3.41
- CING $6.01
- Technical
- Relative Strength Index (RSI)
- COCH 69.25
- CING 53.75
- Support Level
- COCH $0.74
- CING $3.80
- Resistance Level
- COCH $0.85
- CING $4.24
- Average True Range (ATR)
- COCH 0.13
- CING 0.22
- MACD
- COCH 0.04
- CING 0.07
- Stochastic Oscillator
- COCH 70.42
- CING 81.69
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.